Moderna stock gains 3.5 percent to $57.06 as price holds above $56.75 gap open

Moderna stock gains 3.5 percent to $57.06 as price holds above $56.75 gap open
Moderna stock rises 3.5% today

Moderna announced that the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating its investigational mRNA-1469 vaccine for Bundibugyo ebolavirus disease. At the same time, Moderna stock is up 3.4% on the day at $57.06.

Highlights

  • Moderna began dosing participants in a Phase 1 trial in Canada for its investigational mRNA-1469 Bundibugyo ebolavirus vaccine.
  • Shares of Moderna rose 3.4% to $57.06, though analyst sentiment remains mixed and the median price target is below current levels.
  • Technical signals remain divided with shares holding above longer-term support, a gap up at the open, and a forecasted trading range of $54.28 to $59.83 for the week.

The announcement, made by Moderna itself, states that a Phase 1 clinical trial is underway in Canada for mRNA-1469, an investigational vaccine candidate against Bundibugyo ebolavirus disease. The detail that matters is that the first participants have started receiving the vaccine after Health Canada authorized the study. This milestone in the clinical development process is a typical step in biotechnology research and does not signal a change in the company's commercial activities or regulatory status. Contextually, analyst sentiment toward the stock remains mixed, with a median price target below current levels and the most recent rating from Morgan Stanley at equal-weight.

Gap up at open as technical levels split direction

There is no clear link between the news and the latest price action in shares of Moderna, as the timing of the post and the session move cannot be directly connected. Instead, trading is being shaped by technical considerations, with the daily chart showing the price below both the MA-20 and MA-50 but still holding above the MA-200, which points to a divided structure. Notably, a significant gap up at the open stands out against an overall bearish backdrop, while the Stoch RSI nearing oversold territory hints that the recent pullback may be approaching a limit.

Upside bias holds as closing strength guides weekly view

To determine if the move is gaining traction, traders should watch for sustained action above resistance. The session’s most prominent signal was the opening gap from $55.14 to $56.75, setting the tone for early trading interest. From here, the probabilities for the coming trading week show a 33% chance of upside and a 67% chance of downside, with an expected range between $54.28 and $59.83. A close above $58.55 would confirm buyers are following through, while a drop below $52.77 would indicate the move is being faded. On the weekly chart, the broader outlook remains constructive.

Earlier, analysts noted that investors were focused on the commercialization of Moderna's pipeline beyond COVID-19, with the stock exhibiting heightened volatility following quarterly results. The initiation of the mRNA-1469 Phase 1 trial adds an additional clinical catalyst to monitor, but with technical signals still mixed, a sustained move above or below the $58.55 and $52.77 levels, respectively, will be critical for direction in coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.